论文部分内容阅读
目的探讨血清肿瘤标志物对非小细胞肺癌晚期靶向药物治疗疗效的预测作用。方法选择我院2013年2月～2015年4月收治的非小细胞肺癌晚期患者65例为研究对象,均接受靶向药物治疗,对不同疗效患者肿瘤标志物水平进行检测,并对比治疗前后不同疗效患者血清肿瘤标志物水平。结果治疗前,完全缓解+部分缓解患者的癌抗原125(CA125)、角蛋白19的可溶性片段(CYFRA21-1)、癌胚抗原(CEA)等血清肿瘤标志物水平明显高于疾病稳定、疾病进展患者,差异有统计学意义(P<0.05);治疗后,完全缓解+部分缓解患者CA125、CEA、CYFRA21-1等血清肿瘤标志物水平均较治疗前下降(P<0.05),疾病稳定、疾病进展患者的CEA、CA125水平无变化(P>0.05),疾病进展患者治疗后CYFRA21-1水平上升(P<0.05)。结论非小细胞肺癌晚期靶向药物治疗患者通过监测血清肿瘤标志物变化,可预测疗效,具有一定临床意义,值得推广。
Objective To investigate the predictive value of serum tumor markers in the treatment of late-stage targeted drugs for non-small cell lung cancer. Methods Sixty-five patients with advanced non-small cell lung cancer who were treated in our hospital from February 2013 to April 2015 were enrolled in this study. All of them were treated with targeted drugs, and the levels of tumor markers were detected in patients with different therapeutic effects. Efficacy of patients with serum tumor marker levels. Results Serum tumor markers such as CA125, CYFRA21-1 and CEA in patients with complete remission and partial remission were significantly higher than those with stable disease and progression before treatment (P0.05) .After treatment, serum tumor markers such as CA125, CEA and CYFRA21-1 in patients with complete remission and partial remission were lower than those before treatment (P <0.05), the disease was stable, the disease The progress of patients with CEA, CA125 levels did not change (P> 0.05), disease progression in patients with CYFRA21-1 levels increased (P <0.05). Conclusions Patients with advanced NSCLC targeted therapy can predict the therapeutic effect by monitoring the changes of serum tumor markers, which is of clinical significance and worthy of promotion.